According to AlphaMoat, in 2026-08 Ultromics (ultromics.com) received 17,871 monthly visits (-6.9% MoM) — ranked #8,013 of 17,407 AI websites with traffic data, and #1,096 of 3,173 in Industry Services; its largest market is United States (41.9% of visits).
What is Ultromics
Ultromics develops a clinically validated, FDA 510(k)-cleared AI platform (the EchoGo series) that analyzes routine echocardiograms to help identify heart failure with preserved ejection fraction (HFpEF) and cardiac amyloidosis within existing workflows, supporting detection of two severely underdiagnosed diseases. The platform is in use at top U.S. hospitals.
- 01EchoGo Heart Failure uses advanced AI to identify HFpEF patients
- 02EchoGo Amyloidosis screens for cardiac amyloidosis
- 03a single integrated workflow delivers both AI findings
- 04FDA 510(k) clearance and Breakthrough Device designation
- 05CMS assigned CPT Category III code 0932T to EchoGo Heart Failure, supporting a reimbursement path
- 06seamless integration with ultrasound workflows
12-Month Traffic Trend
Visits by Country · Top 5
Popular in Industry Services
Data month: 2026-08 · Visit figures are third-party traffic estimates aggregated monthly — best for scale and trends. Multiple domains of the same product are merged. See methodology.